# A Study of MK-2225 in Healthy Participants (MK-2225-003)

> **NCT06643390** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 32 (actual)

## Conditions studied

- Systemic Sclerosis

## Interventions

- **DRUG:** MK-2225
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06643390
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-21
- **Primary completion:** 2025-07-14
- **Final completion:** 2025-07-14
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2025-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06643390

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06643390, "A Study of MK-2225 in Healthy Participants (MK-2225-003)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06643390. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*